Retrospective Observational Study of the Safety and Toxicity Management of Abemaciclib in Combination with Adjuvant Hormone Therapy in Patients with RH+ ,HER2-nonoveramplified Breast Cancer, Real-life Data (MONARCHE29)

RecruitingOBSERVATIONAL

Enrollment

Participants

Timeline

Start Date

September 26, 2024

Primary Completion Date

October 31, 2025

Study Completion Date

October 31, 2025

Conditions

Brest CancerAbemaciclibAdjuvant TherapyAntineoplastic Combined Chemotherapy ProtocolsBreast Neoplasms

Trial Locations (1)

RECRUITING

Chu Brest, Brest

All Listed Sponsors

lead

University Hospital, Brest

OTHER